Effectiveness calculation in economic analysis: The case of statins for cardiovascular disease prevention

Journal of Epidemiology and Community Health

Volumn 60, Issue 10, 2006, Pages 839-845

  Franco, Oscar H ^a,b   Steyerberg, Ewout W ^b   Peeters, Anna ^c   Bonneux, Luc ^d  

^a UNILEVER RESEARCH   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MONASH UNIVERSITY   (Australia)

^d BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CARDIOVASCULAR DISEASE; DISEASE TREATMENT; DRUG; ECONOMIC ANALYSIS; LIFE TABLE; MODELING;

ARTICLE; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIFE TABLE; MAJOR CLINICAL STUDY; MALE;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COHORT STUDIES; CORONARY DISEASE; COST-BENEFIT ANALYSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE TABLES; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS;

EID: 33749260360     PISSN: 0143005X     EISSN: None     Source Type: Journal    
DOI: 10.1136/jech.2005.041251     Document Type: Article

References (34)

1. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6.
2. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
3. Franco OH, Peeters A, Looman C, et al. Cost-effectiveness of statins in coronary heart disease: systematic review. J Epidemiol Community Health 2005;59:927-33.
4. Bonneux L. How to measure the burden of mortality? J Epidemiol Community Health 2002;56:128-31.
5. Drummond M, Brandt A, Luce B, et al. Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential. Int J Technol Assess Health Care 1993;9:26-36.
6. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275-83.
7. Gompertz B. On the nature of the function expressive of the law of human mortality. Phil Trans Royal Soc London 1825;115:513-83.
8. Kesteloot HE, Verbeke G. On the relationship between all-cause, cardiovascular, cancer and residual mortality rates with age. Eur J Cardiovasc Prev Rehabil 2005;12:175-81.
9. Jonsson B, Johannesson M, Kjekshus J, et al. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian simvastatin survival study (4S). Eur Heart J 1996;17:1001-7.
10. Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999;42:1293-301.
11. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N Engl J Med 1997;336:332-6.
12. Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention or coronary artery disease. Am J Cardiol 1996;78:409-14.
13. Caro J, Klittich W, McGuire A, et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. BMJ 1997;315:1577-82.
14. Szucs TD, Guggenberger G, Berger K, et al. [Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study]. Pharmakookonomische Bewertung von Pravastatin in der Sekundarpravention der koronaren Herzkrankheit bei Patienten mit durchschnittlichen Cholesterinwerten. Eine Analyse fur Deutschland auf der Grundlage der CARE-Studie. Herz 1998;23:319-29.
15. Szucs TD, Berger K, Marz W, et al. [Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial] Kosteneffektivitat von Pravastatin in der koronaren Sekundarpravention bei Patienten mit Myokardinfarkt oder instabiler Angina pectoris in Deutschland. Eine Analyse auf der Grundlage der LIPID-Studie. Herz 2000;25:487-94.
16. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
17. Riviere M, Wang S, Leclerc C, et al. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada. CMAJ 1997;156:991-7.
18. Ganz DA, Kuntz KM, Jacobson GA, et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000;132:780-7.
19. Perreault S, Hamilton VH, Lavoie F, et al. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective? Arch Intern Med 1998;158:375-81.
20. Russell MW, Huse DM, Miller JD, et al. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Can J Clin Pharmacol 2001;8:9-16.
21. Huse DM, Russell MW, Miller JD, et al. Cost-effectiveness of statins. Am J Cardiol 1998;82:1357-63.
22. Hamilton VH, Racicot FE, Zowall H, et al. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. JAMA 1995;273:1032-8.
23. Grover SA, Coupal L, Paquet S, et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999;159:593-600.
24. Grover SA, Coupal L, Zowall H, et al. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? Circulation 2000;102:722-7.
25. Grover SA, Coupal L, Zowall H, et al. How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001;24:45-50.
26. van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat? Eur Heart J 2001;22:751-61.
27. Pharoah PD, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996;312:1443-8.
28. Pickin DM, McCabe CJ, Ramsay LE, et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999;82:325-32.
29. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
30. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
31. Chau J, Cheung BM, McGhee SM, et al. Cost-effectiveness analysis of applying the cholesterol and recurrent events (CARE) study protocol in Hong Kong. Hong Kong Med J 2001;7:360-8.
32. Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000;132:769-79.
33. Tsevat J, Kuntz KM, Orav EJ, et al. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001;141:727-34.
34. Messori A, Santarlasci B, Trippoli S, et al. "Polypill" to fight cardiovascular disease: cost effectiveness of statins for primary prevention of cardiovascular events is questionable. BMJ 2003;327:808-9; discussion 809; author reply 809-10.